微囊化培养对肿瘤细胞耐药性的影响

背景：在微胶囊微环境中肿瘤细胞表现出更接近在体肿瘤的特性。目的：考察微囊化培养对肿瘤细胞耐药性的影响。方法：将平面培养至对数生长期的HepG2细胞微囊化培养15d,再次包封于微胶囊内进行微囊化培养,如此反复3次。回收每次微囊化培养的细胞,并通过显微镜、流式细胞仪、CCK-8和Real Time PCR检测细胞形态、黏附能力、增殖能力、细胞周期、药物敏感性和耐药相关基因的变化。结果与结论：微囊化培养不同次数的细胞再次进行平面培养,其形态、黏附能力、增殖能力和细胞周期均无显著变化。经过微囊化培养后再次进行平面培养,肿瘤细胞的耐药性随着微囊化培养次数的增加而逐渐下降,且耐药性降低的主要原因是耐药相关基因表达下调。提示只有在微胶囊这一独特微环境中肿瘤细胞才能保持高的耐药性,一旦回归平面培养,这一特性便会消失,肿瘤细胞只有在微囊化环境中培养才能表现出类似在体的耐药性

微囊化培养对肿瘤细胞耐药性的影响

背景：在微胶囊微环境中肿瘤细胞表现出更接近在体肿瘤的特性。目的：考察微囊化培养对肿瘤细胞耐药性的影响。方法：将平面培养至对数生长期的HepG2细胞微囊化培养15d,再次包封于微胶囊内进行微囊化培养,如此反复3次。回收每次微囊化培养的细胞,并通过显微镜、流式细胞仪、CCK-8和Real Time PCR检测细胞形态、黏附能力、增殖能力、细胞周期、药物敏感性和耐药相关基因的变化。结果与结论：微囊化培养不同次数的细胞再次进行平面培养,其形态、黏附能力、增殖能力和细胞周期均无显著变化。经过微囊化培养后再次进行平面培养,肿瘤细胞的耐药性随着微囊化培养次数的增加而逐渐下降,且耐药性降低的主要原因是耐药相关基因表达下调。提示只有在微胶囊这一独特微环境中肿瘤细胞才能保持高的耐药性,一旦回归平面培养,这一特性便会消失,肿瘤细胞只有在微囊化环境中培养才能表现出类似在体的耐药性

The enhancement of cancer stem cell properties of hepatocellular carcinoma in 3D scaffolds for modeling cancer in vitro

The enhancement of cancer stem cell properties of hepatocellular carcinoma in 3D scaffolds for modeling cancer in vitr

百花鲫的人工制种及其繁育技术

本发明涉及淡水养殖新对象－百花鲫的人工制种及其繁育技术。选取染色体数目为１６６的彭泽鲫作雌性亲本，白鲫作雄性亲本，通过人工催情、受精、孵化，培育生产百花鲫。以此种方法制种的百花鲫，其受精率为８５－９５％，孵化率为９０－９５％，成活率９０－９５％，生长速度比彭泽鲫快１５－２０％，比普通鲫快２５０％，肉质细嫩，腹部小，含肉量７０％，制种简便，易掌握。在生产养殖中有显著效益

Construction of the Traditional Chinese Medicine external nursing treatment outpatient clinic based on the Guo Hailing Traditional Chinese Medicine Nursing Inheritance Studio (基于“郭海玲中医护理传承工作室”中医护理外治门诊的构建)

Traditional Chinese Medicine (TCM) nursing clinic is an advanced nursing practice with Chinese characteristics. It takes the overall view of TCM and the principle, uses the characteristics of TCM nursing technology to meet the diversified health needs of patients, and plays a unique advantage in disease prevention and health care. TCM nursing clinic is able to improve patient satisfaction, broaden the scope of nursing services and enhance the professional level nursing. However, in the process of its development, there are also bottlenecks such as prescription right, inability to follow, and weak discipline development. The construction of Traditional Chinese Medicine Nursing Inheritance Studio is effective to drive the development of disciplines, develop the inheritance of TCM nursing, and realize mutual promotion and mutual development. (中医护理门诊是一种具有中国特色的高级护理实践模式, 其以中医的整体观和辨证施护为原则, 运用中医特色护理技术, 满足患者多元化的健康需求, 在疾病预防保健中发挥着独特优势。中医护理门诊能够提升患者满意度, 拓宽护理工作服务范围, 提升护理专业化水平。但是其发展过程中也有处方权、无法可依、学科发展薄弱等瓶颈, 中医护理传承工作室的建设, 可以有效带动学科发展, 发成中医护理传承, 实现相互促进相互发展。

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials